Correspondence 0001193125-24-153024 from NEKTAR THERAPEUTICS (NKTR)
NEKTAR THERAPEUTICS
Date: June 3, 2024 · CIK: 0000906709 · Accession: 0001193125-24-153024
AI Filing Summary & Sentiment
File numbers found in text: 333-279760
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Ms. Tamika Sheppard Requested Date: June 5, 2024 Requested Time: 4:05 p.m., Eastern Time
Re:
Dear Ms. Sheppard:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Nektar Therapeutics (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 5, 2024, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Sam Zucker at (650) 752-3232.
If you have any questions regarding this request, please contact Sam Zucker of Goodwin Procter LLP at (650) 752-3232.
Sincerely,
NEKTAR THERAPEUTICS
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR June 3, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Tamika Sheppard Re: Nektar Therapeutics Acceleration Request for Registration Statement on Form S-3 File No. 333-279760 Acceleration Request Requested Date: June 5, 2024 Requested Time: 4:05 p.m., Eastern Time Dear Ms. Sheppard: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Nektar Therapeutics (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 5, 2024, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Sam Zucker at (650) 752-3232. If you have any questions regarding this request, please contact Sam Zucker of Goodwin Procter LLP at (650) 752-3232. Sincerely, NEKTAR THERAPEUTICS /s/ Mark A. Wilson Mark A. Wilson General Counsel Nektar Therapeutics cc: Howard W. Robin, Chief Executive Officer, President and Director, Nektar Therapeutics Sandra Gardiner, Chief Financial Officer, Nektar Therapeutics Mitchell S. Bloom, Esq., Goodwin Procter LLP Sam Zucker, Esq., Goodwin Procter LLP